[{"id":"f3ac4815-2f53-4f41-ad02-7d53872a3806","acronym":"SOUNDTRACK-C1","url":"https://clinicaltrials.gov/study/NCT07509151","created_at":"2026-04-11T01:36:47.704Z","updated_at":"2026-04-11T01:36:47.704Z","phase":"Phase 3","brief_title":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)","source_id_and_acronym":"NCT07509151 - SOUNDTRACK-C1","lead_sponsor":"AstraZeneca","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e surovatamig (AZD0486)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 04/08/2026","start_date":" 04/08/2026","primary_txt":" Primary completion: 11/29/2032","primary_completion_date":" 11/29/2032","study_txt":" Completion: 08/29/2033","study_completion_date":" 08/29/2033","last_update_posted":"2026-04-03"}]